792 research outputs found
Babel, or the local distortion of the Greek language
No full textTitle: Βαβυλωνία ἤ ἡ κατά τόπους διαφθορά τῆς ἑλληνικῆς γλώσσας. Κωµωδία (Babel, or the local distortion of the Greek language: A comedy) Originally published: Ναύπλιο (Nafplio), Τυπογραφεῖsο Κωνσταντίνου Τόµπρα ἐκ Κυδωνιῶν καὶ Κωνσταντίνου Ἰωαννίδη ἐκ Σµύρνης, 1836 Language: Greek The excerpt used is from D. C. Vyzantios, Βαβυλωνία, introduction by Spyros Evangelatos (Athens: Εστία, 1993), pp.1–3. About the author Dimitrios Vyzantios (pseudonym of Dimitrios K. Hatziaslanis) [1790, Constantin..
Dimitrios Tsamis Karatasos : a symbol of Greek, Serbian and Bulgarian friendship
No full textTwo Serbian texts extol the contribution of Dimitrios Tsamis Karatasos to the Balkan joint effort to throw off the Ottoman yoke. These texts are analysed by the author within the historical framework of their period, so that the man’s personality and work may be accurately evaluated from a fresh viewpoint. More specifically, the author conducts a research on the tombstone of Dimitrios Tsamis Karatasos, which he discovered himself at Naoussa, and the octet engraved on it, which is also published here. The work is illustrated by seven plates, of which four have not been published previously
The Remains of authoritarianism : bureaucracy and civil society in post-authoritarian Greece
No full textDimitrios A. Sotiropoulos. 30 cm. He presented this paper at a seminar held at the Center on October 21, 1994. - T.p. Includes bibliographical references (p. 31-35
Erratum: Korkovelos, A., et al. The role of open access data in geospatial electrification planning and the achievement of SDG7. An OnSSET-based case study for Malawi. <i>Energies</i> 2019, 12(7), 1395
No full textThe authors wish to make a change in author names (adding new author—Dimitrios Mentis) to this paper
Supplementary_Table_2 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
No full textSupplemental material, Supplementary_Table_2 for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial by Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O’Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O’Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O’Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne and John Crown in Therapeutic Advances in Medical Oncology</p
Supplementary_Table_1 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
No full textSupplemental material, Supplementary_Table_1 for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial by Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O’Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O’Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O’Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne and John Crown in Therapeutic Advances in Medical Oncology</p
Supplementary_Table_3 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
No full textSupplemental material, Supplementary_Table_3 for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial by Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O’Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O’Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O’Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne and John Crown in Therapeutic Advances in Medical Oncology</p
Supplementary_Methods – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
No full textSupplemental material, Supplementary_Methods for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial by Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O’Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O’Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O’Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne and John Crown in Therapeutic Advances in Medical Oncology</p
Novel targeted agents in Her-2 positive and triple negative breast cancer
No full textThe development of Her-2 targeted therapies has improved the prognosis for patients with Her-2 positive breast cancer. However, not all Her-2 positive tumours respond to treatment with Her-2 antagonists. Triple negative cancers are resistant to hormone and Her-2 targeted therapies. This project focused on improving response in Her-2 overexpressing breast cancer and on developing effective targeted therapy strategies for triple negative breast cancer.
We tested a number of multi-target kinase inhibitors (imatinib, sunitinib, pazopanib and dasatinib) in Her-2 positive and triple negative breast cancer cell lines, alone and in combination with other agents.
Two of the Her-2 positive cell lines showed moderate sensitivity to sunitinib malate. Combined treatment with sunitinib and trastuzumab showed improved response compared to either drug alone, in the four Her-2 positive cell lines tested.
Dasatinib inhibited growth in 3 of the 5 triple negative but in only 1 of the 4 Her-2 positive cell lines tested. Based on response to the other multi-target kinase inhibitors, which have overlapping target specificities, and the Src,PP2, our results suggest that sensitivity to dasatinib in triple negative breast cancer is due to inhibition of ephrin type A receptors. Consistent with this hypothesis, neither Src expression nor phosphorylation predicted sensitivity to dasatinib, but high levels of Ephrin type A receptor 2 protein correlated with dasatinib sensitivity. High levels of caveolin 1 and caveolin 2 also correlated with dasatinib sensitivity in the panel of cell lines.
Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive cell lines. Dasatinib, in combination with 5’-deoxy-5’-fluoruridine, displayed synergy or additivity. Moderate synergy was observed with docetaxel in two triple negative cell lines.
In conclusion, we have identified dasatinib with cisplatin as a rational combination for testing in triple-negative breast cancer, and have identified a panel of putative predictive biomarkers for dasatinib sensitivity (EphA2, CAV1 and CAV2)
The Exemplary Life of Dimitrios Vikelas (1835-1908)
No full textThis paper describes the "satisfying curve" of Dimitrios Vikelas' life journey, starting from Syros in 1835, moving via Constantinople, Odessa, and Syros again, to London, Paris and finally Athens. It explores Vikelas' multiple aspects, as merchant, writer, traveller, lecturer and essayist, Olympic founder, educationalist, book collector and philanthropist, all of which were united in the public-spirited man of letters (logios). It sets Vikelas in the context of the Greek commercial diaspora, the world of the London expatriate Greek community, and the dynamic society of late nineteenth-century Athens, beginning in the 1870s to act as a magnet to Greek expatriates. The author stresses two qualities of Vikelas: his belief in the idea of a progressive Greek state marked by advances in education, culture, tourism and standards of public life; and the self-awareness and experience which inform his autobiographical writings, not only his memoir My Life but also his last such work, The War of 1897
- …
